23806-76-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(benzyloxy)-3-methoxybenzoic acid is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its versatile structure allows for the creation of a wide range of molecules with potential therapeutic applications.
Used in Research and Development:
2-(benzyloxy)-3-methoxybenzoic acid is used as a research compound for studying its potential therapeutic properties, such as anti-inflammatory and anticancer activities. This helps in the development of new drugs and understanding the compound's pharmacological effects.
Used in Drug Delivery Systems:
2-(benzyloxy)-3-methoxybenzoic acid may be used in the development of drug delivery systems, where its chemical properties can be exploited to improve the delivery, bioavailability, and therapeutic outcomes of various pharmaceuticals. This could involve the use of organic or metallic nanoparticles as carriers for the compound, aiming to enhance its efficacy and overcome limitations in its application.

Upstream product

• 100-39-0 benzyl bromide 
• 339539-06-9 methyl 2-(benzyloxy)-3-methoxybenzoate 
• 6342-70-7 3-methoxymethylsalicylate 
• 877-22-5 3-methoxysalicylic acid 
• 210706-41-5 2-Benzyloxy-3-methoxy-benzoic acid benzyl ester 

Downstream Products

• 87307-77-5 1-<3-methoxy-2-(phenylmethoxy)phenyl>ethanone 
• 703-98-0 1-(2-hydroxy-3-methoxyphenyl)ethanone 
• 33051-28-4 ethyl 2-(2-acetyl-6-methoxyphenoxy)acetate 
• 33051-29-5 2-(2-acetyl-6-methoxyphenoxy)acetic acid 
• 33038-10-7 7-methoxy-3-methyl-1-benzofuran 
• 1394063-63-8 C₂₂H₂₀FNO₃ 
• 610320-80-4 N-(4-fluorobenzyl)-3-methoxysalicylamide 
• 905719-12-2 2-benzyloxy-3-methoxy-benzoyl chloride 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

HIV INTEGRASE INHIBITORS

Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof.

7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B

This invention relates to compounds of Formula I that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.

Enterobactin protonation and iron release: Hexadentate tris-salicylate ligands as models for triprotonated ferric enterobactin1

Enterobactin mediates iron uptake in Escherichia coli and related bacteria. The structure of the neutral protonated ferric enterobactin complex Fe[H3enterobactin] has been the source of some controversy in the literature. The coordination chemistry of the new model ligands tris[(2- hydroxybenzoyl)-2-aminoethyl]amine (TRENSAM) and tris[(2-hydroxy-3- methoxybenzoyl),2-aminoethyl]amine (TREN(3M)SAM demonstrate the previously proposed tris-salicylate mode of binding for ferric enterobactin; they form 1:1 metal - ligand complexes with Fe3+ and Al3+ that bind the metals through tris-salicyiato coordination (i.e. the chelate is a six-membered metallocycle with the phenolic and amide oxygens binding the metal center). The ferric and aluminum complexes of TRENSAM are isostructural and crystallize in the monoclinic space group P21/c. The ferric and aluminum complexes of TREN(3M)SAM are nearly isostructural and crystallize in the triclinic space group P1, with the same salicylate mode of bonding as the TRENSAM complexes. The TRENSAM ligand and its metal complexes have been investigated by NMR, potentiometric, and spectrophotometric techniques, and the results of these experiments are compared to Fe[H3enterobactin] and a biomimetic analogue Fe[H3MECAM] (which supports growth of E. coli). The properties of Fe[TRENSAM] and Fe[TREN(3M)SAM] represent an iron release pathway for synthetic analogues of enterobactin that are not susceptible to the degradative pathway usual for enterobactin.